These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 25937170)

  • 1. A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior.
    Vardy E; Robinson JE; Li C; Olsen RHJ; DiBerto JF; Giguere PM; Sassano FM; Huang XP; Zhu H; Urban DJ; White KL; Rittiner JE; Crowley NA; Pleil KE; Mazzone CM; Mosier PD; Song J; Kash TL; Malanga CJ; Krashes MJ; Roth BL
    Neuron; 2015 May; 86(4):936-946. PubMed ID: 25937170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using opioid receptors to expand the chemogenetic and optogenetic toolbox.
    Damez-Werno DM; Kenny PJ
    Neuron; 2015 May; 86(4):853-855. PubMed ID: 25996128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats.
    Marchant NJ; Whitaker LR; Bossert JM; Harvey BK; Hope BT; Kaganovsky K; Adhikary S; Prisinzano TE; Vardy E; Roth BL; Shaham Y
    Neuropsychopharmacology; 2016 Jan; 41(2):402-9. PubMed ID: 26019014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemogenetic manipulation of neurons.
    Vogt N
    Nat Methods; 2015 Jul; 12(7):603. PubMed ID: 26339707
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemogenetic silencing of neurons in the mouse anterior cingulate area modulates neuronal activity and functional connectivity.
    Peeters LM; Hinz R; Detrez JR; Missault S; De Vos WH; Verhoye M; Van der Linden A; Keliris GA
    Neuroimage; 2020 Oct; 220():117088. PubMed ID: 32592851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for selective activation of DREADD-based chemogenetics.
    Zhang S; Gumpper RH; Huang XP; Liu Y; Krumm BE; Cao C; Fay JF; Roth BL
    Nature; 2022 Dec; 612(7939):354-362. PubMed ID: 36450989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
    Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
    ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.
    Zhu H; Aryal DK; Olsen RH; Urban DJ; Swearingen A; Forbes S; Roth BL; Hochgeschwender U
    Genesis; 2016 Aug; 54(8):439-46. PubMed ID: 27194399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.
    Nagai Y; Miyakawa N; Takuwa H; Hori Y; Oyama K; Ji B; Takahashi M; Huang XP; Slocum ST; DiBerto JF; Xiong Y; Urushihata T; Hirabayashi T; Fujimoto A; Mimura K; English JG; Liu J; Inoue KI; Kumata K; Seki C; Ono M; Shimojo M; Zhang MR; Tomita Y; Nakahara J; Suhara T; Takada M; Higuchi M; Jin J; Roth BL; Minamimoto T
    Nat Neurosci; 2020 Sep; 23(9):1157-1167. PubMed ID: 32632286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
    Urban DJ; Roth BL
    Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.
    Braida D; Limonta V; Pegorini S; Zani A; Guerini-Rocco C; Gori E; Sala M
    Psychopharmacology (Berl); 2007 Mar; 190(4):441-8. PubMed ID: 17219220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral Vector Delivery of DREADDs for CNS Therapy.
    Pickering CA; Mazarakis ND
    Curr Gene Ther; 2021; 21(3):191-206. PubMed ID: 33573551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DREADDs for Neuroscientists.
    Roth BL
    Neuron; 2016 Feb; 89(4):683-94. PubMed ID: 26889809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.
    Lee DY; He M; Liu-Chen LY; Wang Y; Li JG; Xu W; Ma Z; Carlezon WA; Cohen B
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5498-502. PubMed ID: 16945525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
    Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
    Burnett CJ; Krashes MJ
    J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues.
    Lee DY; He M; Kondaveti L; Liu-Chen LY; Ma Z; Wang Y; Chen Y; Li JG; Beguin C; Carlezon WA; Cohen B
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4169-73. PubMed ID: 16051487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
    Harding WW; Tidgewell K; Byrd N; Cobb H; Dersch CM; Butelman ER; Rothman RB; Prisinzano TE
    J Med Chem; 2005 Jul; 48(15):4765-71. PubMed ID: 16033256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DREADD: a chemogenetic GPCR signaling platform.
    Zhu H; Roth BL
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25522378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemogenetic approaches to identify metabolically important GPCR signaling pathways: Therapeutic implications.
    Meister J; Wang L; Pydi SP; Wess J
    J Neurochem; 2021 Aug; 158(3):603-620. PubMed ID: 33540469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.